title: Clinical impact and biomaterial evaluation of autologous platelet gel in cardiac surgery.
abstract: We compared the clinical efficacy of autologous platelet gel (APG) and gelatine (CONT), including biomaterial evaluation. In a prospective, randomized, controlled trial, 64 patients undergoing complex coronary artery bypass graft (CABG) surgery and/or aortic surgery, in whom the surgeon was able to identify a bleeding site for which conventional means to stop bleeding were impractical or proved unsuccessful, were enrolled. Aortic punch biopsy from each patient was harvested in explant cell (EC) culture media. Hemostasis success for the "oozing" category was 89% in APG and 60% in CONT (p< 0.05). For the "heavy bleeding" category, the success rates were 92% in APG and 45% in CONT (p<0.01). Contact of gelatine inhibited EC proliferation and APG increased cell cycling and EC quantity. Phagocytic capacity (PC) was significantly higher in the APG group (p<0.001). APG was significantly better than CONT with respect to hemostatic success rate, effects on wound healing and increased resistance to infection (PC).
authors.affiliation: University of Kirikkale, Turkey. sgunaydin@isnet.net.tr
authors.forename: S
authors.initials: S
authors.lastname: Gunaydin
authors.forename: K
authors.initials: K
authors.lastname: McCusker
authors.forename: T
authors.initials: T
authors.lastname: Sari
authors.forename: Ma
authors.initials: M
authors.lastname: Onur
authors.forename: A
authors.initials: A
authors.lastname: Gurpinar
authors.forename: H
authors.initials: H
authors.lastname: Sevim
authors.forename: P
authors.initials: P
authors.lastname: Atasoy
authors.forename: C
authors.initials: C
authors.lastname: Yorgancioglu
authors.forename: Y
authors.initials: Y
authors.lastname: Zorlutuna
mesh_terms: D000368:Aged; D049109:Cell Proliferation / Q000187:drug effects; D002478:Cells, Cultured; D001026:Coronary Artery Bypass; D042783:Endothelial Cells / Q000187:drug effects; D005780:Gelatin / Q000008:administration & dosage / Q000009:adverse effects*; D005782:Gels / Q000008:administration & dosage / Q000009:adverse effects*; D006488:Hemostasis, Surgical; D006801:Humans; D008297:Male; D008422:Materials Testing; D010587:Phagocytosis / Q000187:drug effects; D010982:Platelet-Derived Growth Factor / Q000032:analysis; D053657:Platelet-Rich Plasma; D011446:Prospective Studies; D001620:beta-Thromboglobulin / Q000032:analysis
chemical_list: D005782:Gels; D010982:Platelet-Derived Growth Factor; D001620:beta-Thromboglobulin; D005780:Gelatin